‘Global Women’s Healthcare Market Worth $37.5bn In 2021’ Says Visiongain Report

15 August 2018
Pharma

Visiongain’s new report Global Women’s Healthcare Market Forecast 2017-2027: Postmenopausal Osteoporosis, Hormonal Contraceptives, Menopause, Infertility, Endometriosis, Polycystic Ovary Syndrome indicates that the global women’s healthcare market will see $37.5bn in spending in 2021.

The revenue of the women’s healthcare market in 2016 is estimated at $31.1bn and is expected to grow at a CAGR of 3.8% in the first half of the forecast period. Among various segments in the Women’s Healthcare market, the Postmenopausal Osteoporosis segment dominated the Global Women's Healthcare market with a share of 36.99% in 2016.
The lead analyst of the report said: “ The Global Women's Healthcare market is driven by several factors, of which the increasing aging female population is one of the major drivers. With the increase in age and onset of menopause, women's risk factors for various conditions are high. The expected launch of pipeline molecules is another driver in this market.
The 154-page report contains 95 charts that add visual analysis in order to explain the developing trends within the Global Women’s Healthcare Market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the global women’s healthcare market and its leading submarkets: Postmenopausal Osteoporosis, Hormonal Contraceptives, Menopause, Infertility, Endometriosis, Polycystic Ovary Syndrome
The 154-page report offers market forecasts for the leading regional and national markets: US and Latin America, Japan, the UK, Germany, France, Spain, Italy, Rest of Europe, Rest of the World.
This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval. This report also discusses the drivers, challenges and trends that affect the global women’s healthcare market

Moreover, our work discusses the leading companies in the women’s healthcare market. Our study also discusses the SWOT Analysis of the submarkets and leading companies.

The report Global Women’s Healthcare Market Forecast 2017-2027: Postmenopausal Osteoporosis, Hormonal Contraceptives, Menopause, Infertility, Endometriosis, Polycystic Ovary Syndrome report will be of value to anyone who wants to better understand the global women’s healthcare market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the global women’s healthcare market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever